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ABSTRACT
Hereditary mutations in polynucleotide kinase-
phosphatase (PNKP) result in a spectrum of neu-
rological pathologies ranging from neurodevelop-
mental dysfunction in microcephaly with early on-
set seizures (MCSZ) to neurodegeneration in ataxia
oculomotor apraxia-4 (AOA4) and Charcot-Marie-
Tooth disease (CMT2B2). Consistent with this, PNKP
is implicated in the repair of both DNA single-
strand breaks (SSBs) and DNA double-strand breaks
(DSBs); lesions that can trigger neurodegeneration
and neurodevelopmental dysfunction, respectively.
Surprisingly, however, we did not detect a signifi-
cant defect in DSB repair (DSBR) in primary fibrob-
lasts from PNKP patients spanning the spectrum
of PNKP-mutated pathologies. In contrast, the rate
of SSB repair (SSBR) is markedly reduced. More-
over, we show that the restoration of SSBR in pa-
tient fibroblasts collectively requires both the DNA
kinase and DNA phosphatase activities of PNKP, and
the fork-head associated (FHA) domain that interacts
with the SSBR protein, XRCC1. Notably, however, the
two enzymatic activities of PNKP appear to affect dif-
ferent aspects of disease pathology, with reduced
DNA phosphatase activity correlating with neurode-
velopmental dysfunction and reduced DNA kinase
activity correlating with neurodegeneration. In sum-
mary, these data implicate reduced rates of SSBR,
not DSBR, as the source of both neurodevelopmental
and neurodegenerative pathology in PNKP-mutated
disease, and the extent and nature of this reduction
as the primary determinant of disease severity.
INTRODUCTION
DNA strand breaks can arise endogenously or can result
from exogenous sources of DNA damage such as ionizing
radiation and chemical genotoxins. To combat the geno-
toxic impact of DNA damage, cells have evolved multiple
biochemical pathways to detect and repair DNA strand
breaks (1,2). Importantly, defects in DNA strand break re-
pair can result in a variety of different disease patholo-
gies, highlighting the threat posed by DNA breaks to hu-
man health (3–5). For example, microcephaly and devel-
opmental delay are often present in individuals with de-
fects in non-homologous end-joining (NHEJ); one of the
two major pathways by which DNA double-strand breaks
(DSBs) are repaired (4). In contrast, the primary pathol-
ogy resulting from defects in the repair of DNA single-
strand breaks (SSBs) is neurodegeneration, and in partic-
ular progressive cerebellar ataxia (5,6). Examples of the
latter are individuals with spinocerebellar ataxia with ax-
onal neuropathy 1 (SCAN1), ataxia with oculomotor apraxia
type 1 (AOA1), and ataxia with oculomotor apraxia-XRCC1
(AOA-XRCC1), in which theDNA strand break repair pro-
teins TDP1, aprataxin, and XRCC1 are mutated, respec-
tively (7–10).
Arguably one of the most common sources of neurolog-
ical disease associated with defects in DNA strand break
repair are mutations in the enzyme polynucleotide kinase-
phosphatase (PNKP) (11). PNKP possesses both DNA 5′-
kinase and DNA 3′-phosphatase activity and thereby can
convert 5′-hydroxyl and 3′-phosphate termini to the canon-
ical 5′-phosphate and 3′-hydroxyl moieties necessary for
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completion of DNA strand break repair (12,13). Whereas
3′-phosphate termini are present at ∼70% of DNA breaks
induced by reactive oxygen species and ionising radiation,
both 3′-phosphate and 5′-hydroxyl termini are generated
at DNA strand breaks induced by the abortive activity
of topoisomerase 1 (TOP1) (14,15). Notably, PNKP inter-
acts with protein complexes involved in the repair of SSBs
and DSBs in mammalian cells via the interaction of its
amino-terminal FHA domain with the SSBR and DSBR
scaffold proteins XRCC1 (16–18) and XRCC4 (19–22),
respectively.
Mutations in PNKP result in three clinically distinct neu-
rological diseases. The most severe of these is microcephaly
with early onset seizures (MCSZ), a neurodevelopmental
disease associated with microcephaly, early-onset seizures
and developmental delay (23). In addition, PNKP muta-
tions are the cause of the neurodegenerative disease ataxia
with oculomotor apraxia 4 (AOA4), which exhibits progres-
sive cerebellar atrophy and ataxia oculomotor apraxia (24–
26). Strikingly, some affected individuals possess elements
of both of these diseases; presentingwith bothmicrocephaly
and progressive cerebellar atrophy (26–30). Finally, PNKP
mutations were also identified recently in Charcot-Marie-
Tooth disease 2B2 (CMT2B2), which is associated withmild
axonal peripheral polyneuropathy and relatively late-onset
cerebellar ataxia (31–33).
Here, we have addressed the relationship between defects
in SSBR, DSBR, and neurological pathology in patient-
derived cells from individuals with mutations in PNKP
spanning the spectrum of PNKP-associated pathologies.
Surprisingly, our data implicate unrepaired SSBs as the
source of both the neurodevelopmental and neurodegener-
ative pathology in PNKP-associated disease, and the level
of residual SSBR as the primary determinant of disease
severity. Our data also implicate the two activities of PNKP
in different aspects of the disease pathology; with reduced
DNA phosphatase and DNA kinase activity correlating
best with neurodevelopmental dysfunction and neurode-
generation, respectively.
MATERIALS AND METHODS
Cell lines
The control human primary fibroblasts 1BR3 (denoted here
as 1BR) and the PNKP patient-derived primary fibrob-
lasts AOA4/MCSZ (7,26), MCSZ-I (34), CMT2B2-(I-V)
(32) and XRCC1 patient-derived primary fibroblasts (7)
were grown in Minimum Essential Media (MEM, Gibco)
supplemented with 15% fetal bovine serum, 2 mM glu-
tamine and the antibiotics penicillin (100 units/ml) and
streptomycin (100 g/ml). Lymphoblastoid cells (LCLs)
derived fromCMT2B2 patients with a pathogenic heterozy-
gous mutation (p.Y145S) in myelin protein zero (denoted
here CMT-control), PNKP patients CMT2B2-(I-VI) (32),
AOA4-I (25), AOA4-II and father andmother parental con-
trols (35), and ‘WT’ control LCLs were grown in RPMI-
1640 Media (Sigma) supplemented with 10% fetal bovine
serum and the antibiotics as above in a humidified atmo-
sphere of 5% CO2 at low oxygen (5%) at 37◦C.
siRNA transfection
Where indicated, cells were transfected with mix of ei-
ther PNKP siRNA #1: 5′-CCGGAUAUGUCCACGUG
AA-3′ and PNKP siRNA #2: 5′-GGAAACGGGUCGC
CAUCGA-3′ or non-target siRNA #1: 5′-UGGUUUA
CAUGUCGACUAA-3′ and non-target siRNA #2: 5′-U
GGUUUACAUGUUGUGUGA-3′) using Lipofectamine
RNAiMAX (Life Technologies) 48–72 h before experiment.
Constructs, protein purification and transfection
Wild-type recombinant human PNKP (PNKPWT) and
PNKP with a mutated FHA domain (R35A; PNKPFHA)
or catalytically inactive phosphatase domain (D171N;
PNKPPD) harboured an N-terminal His tag if expressed
from the bacterial expression construct pET16b or N-
terminal EYFP if expressed from the mammalian expres-
sion construct pEYFP-C1. PNKP proteins were expressed
in E.coli from pET16b and purified by metal-chelate affin-
ity chromatography and gel filtration. For transfection of
human cells with purified recombinant PNKP, 2 g of con-
trol bovine serum albumin (BSA) or the indicated PNKP
protein was electroporated into 2×105 primary human fi-
broblasts using a NEON Transfection System (Invitrogen)
according to themanufacturer’s instructions. Cells were em-
ployed for experiments 18 h post-transfection. For transfec-
tion with mammalian expression constructs, 1 g of con-
trol pEYFP-C1 or pEYFP-C1 encoding wild type or the
indicated mutant PNKP were electroporated into 2×105
primary human fibroblasts as described above. Transfected
cells were employed in experiments 48 h post-transfection.
Antibodies and western blotting
Primary antibodies were anti-pan-ADP-ribose binding
reagent (MABE1016, Millipore), anti-PNKP N-terminal
(ab170954, Abcam), anti-PNKP C-terminal (ab18107,
Abcam), anti- actin (66009, Proteintech), anti-H2AX
(9718, Cell Signaling), and anti-PCNA (sc-56, Santa Cruz
Biotechnology). Secondary antibodies for western blotting
were horseradish peroxidase (HRP)-conjugated goat anti-
rabbit (170-6515, Bio-Rad) and goat anti-mouse (170-6516,
Bio-Rad) and for indirect immunofluorescence were don-
key anti-rabbit Alexa 488 (A21206, Invitrogen) and donkey
anti-mouse Alexa 647 (A-31571, Invitrogen). Samples for
western blotting were lysed in SDS sample buffer and sub-
jected to SDS-PAGE, transferred onto nitrocellulose mem-
brane and detected by the appropriate specific primary and
HRP-conjugated secondary antibodies.
Alkaline comet assays
The level of DNA strand breaks was evaluated by alkaline
comet assays following DMSO treatment or treatment with
10MCPT for 60min at 37◦Cor following irradiation with
20 Gy of X-rays (X-RAD 225XL, Accella) with indicated
time of recovery. The average comet tail moment in 100 cells
per sample was evaluated by Comet Assay IV software (Per-
ceptive Instruments).
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Indirect immunofluorescence microscopy
For indirect immunofluorescence microscopy, cells were
cultured and treated where indicated with 10 M CPT
(C9911, Sigma) for 45 min, irradiated (X-RAD 225XL,
Accella) with 20 Gy of X-rays on ice or 2 Gy of X-rays
at RT in the presence of DMSO (D2650, Sigma), 10 M
PARG inhibitor (PDD 0017273; 5952, Tocris Bioscience)
or 5 M DNA-PK inhibitor (NU 7441; 3712, Tocris Bio-
science). Cells were fixed with 4% formaldehyde and im-
munostained as described previously (7). Images were taken
using a DMi6000 microscope (Leica) with 40× dry objec-
tive. Automated wide-field microscopy was performed on
scanR system (Olympus) with scanR Image Acquisition
and Analysis Software, 40 x/0.95NA (UPLSAPO 2 40×)
dry objective.
DSBR assays
To measure DSBR, cells were pre-extracted with 0.2%
Triton-X 100 for 2 min on ice prior fixation. Cells were
stained for PCNA, H2AX, and counterstained for DNA
using 1 g/ml DAPI (202710100, Acros). The cell cycle
phase was determined based on the presence of PCNA sig-
nal and the DNA content of individual cell nuclei. PCNA-
positive cells were gated as S phase cells, and the DNA con-
tent of PCNA-negative cells was compared to gate cells in
G1 phase or G2 phase . Cells that could not be gated based
on these criteria were excluded from the analysis.
PNKP biochemical activity
PNKP substrate was prepared by annealing equimolar
amounts of fluorophore-labeled deoxyriboligonucleotides
(MidlandCertifiedReagentCompany). Tomeasure both 3′-
phosphatase and 5′-kinase activities, oligonucleotides with
3′-phosphate ‘S1’ [5′-(TAMRA)-TAGCATCGATCAGTC
CTC-3′-P] and 5′-hydroxyl ‘S2’ [5′-OH-GAGGTCTAGCA
TCGTTAGTCA-(6-FAM)-3′] were annealed to a comple-
mentary strand oligonucleotide [5′-TGACTAACGATGC
TAGACCTCTGAGGACTGATCGATGCTA-3′] in an-
nealing buffer (10 mM Tris pH 7.5, 200 mM NaCl,
1 mM EDTA) (36). To test only 3′-phosphatase ac-
tivity, ‘S1’ was used in a combination with ‘C2’ [5′-P
-GAGGTCTAGCATCGTTAGTCA-(6-FAM)-3′] and to
test only 5′-kinase activity, ‘S2’ was used in a combina-
tion with ‘C1’ [5′-(TAMRA)-TAGCATCGATCAGTCCT
C-3′-OH]. Cell-free protein extracts were prepared in lysis
buffer [25 mM Tris, pH 7.5, 10 mM EDTA, 10 mM EGTA,
100 mM NaCl, 1 % Triton X-100, cOmplete protease in-
hibitors (Roche)], incubated on ice for 15 min and cen-
trifuged at 16 000× g, 20min at 4◦C.The indicated amounts
of purified PNKP proteins or cell-free protein extracts
were incubated with 50 nM substrate and 1 M single-
stranded nuclease competitor oligonucleotide [5′-AAAGA
TCACAAGCATAAAGAGACAGG-3′] in reaction buffer
(25 mM Tris, pH 7.5, 130 mM KCl, 10 mM MgCl2, 1 mM
DTT, 1 mMATP) at 37◦C for 10 or 60 min. 50 l reactions
were terminated by addition of 50l quenching buffer (90%
formamide, 50 mM EDTA, 0.006% Orange G). 10 l of
each reaction was separated on a 20% denaturing polyacry-
lamide gel and analyzed on a PharosFX Molecular Imager
System (Bio-Rad).
RESULTS
Reduced PNKP protein and activity in PNKP patient-derived
fibroblasts
To identify the DNA strand break repair defects in PNKP-
associated neurological disease we initially employed pri-
mary human fibroblasts derived from two PNKP-mutated
individuals spanning the spectrum of PNKP-related disease
pathologies and, as a control, primary human fibroblasts
derived from an unaffected individual (1BR). One of the af-
fected individuals (MCSZ-I) is a patient with MCSZ and is
a compound heterozygote harbouring a 1-bp duplication in
the FHA domain in one allele (c.63dupC) and a 10-bp dele-
tion spanning the exon14/intron14 splice site in the DNA
kinase domain in the second allele (c.1295 1298) (Figure
1A) (34). Both of these mutations are predicted to result in
translational frameshifts in, or upstream of, the DNA 5′-
kinase domain. The second affected individual is a patient
with combined AOA4/MCSZ and is homozygous for a 17-
bp duplication in exon 14 (c.1250 1266dup), which again
results in a translational frameshift within the DNA kinase
domain (Figure 1A) (26).
Both MCSZ-I and AOA4/MCSZ cells possess a very
small amount of residual PNKP protein, as measured
by western blotting (Figure 1B). The residual PNKP in
AOA4/MCSZ cells migrated faster than wild type PNKP
and was detected only by an N-terminal-specific antibody,
consistent with both PNKP alleles in this cell line en-
coding a severely truncated 5′-kinase domain. In contrast,
the residual PNKP in MCSZ-I cells migrated at two po-
sitions; one that was close to full-length PNKP and de-
tected by both N- and C-terminal antibodies and one that
was severely truncated and detected by N-terminal anti-
body. AOA4/MCSZ cells lacked detectable 5′-kinase activ-
ity, consistent with the truncated DNA kinase domain, but
did possess a small amount of residual 3′-phosphatase ac-
tivity, as measured by the appearance of a small amount
of fully repaired (ligated) 3′-phosphate oligonucleotide sub-
strate (Figure 1C). In contrast, consistent with our previous
report (34),MCSZ-I cells exhibited significant levels of both
DNA 3′-phosphatase and 5′-kinase activity (Figure 1C).
The residual 5′-kinase activity in this cell line is most likely
encoded by the small amount of near-full length PNKP
polypeptide detected in this cell line, resulting from alter-
native splicing and/or translation-initiation downstream of
the mutated FHA domain (34).
Normal rates of DSBR in PNKP patient-derived fibroblasts
Defects in the repair of DSBs by NHEJ resulting
from hereditary mutations in XRCC4, DNA lig-
ase IV, or Cernunnos/XLF are strongly implicated in
neurodevelopmental/microcephalic pathologies similar to
those observed in individuals with mutations in PNKP
(37–41). Consequently, because PNKP has been shown
to be involved in NHEJ (19,20,42), it seemed plausible
that unrepaired DSBs might contribute to PNKP-mutated
disease. To address this possibility, we employed scanR
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Figure 1. Reduced PNKP protein and activity in PNKP patient-derived fibroblasts. (A) Cartoon showing PNKP functional domains and the mutations
present in the patient-derived fibroblast cell lines MCSZ-I and AOA4/MCSZ. The former is compound heterozygous for two frame-shift mutations and
the latter is homozygous for a single frame-shift mutation. The location of the epitopes detected by the N- and C-terminal antibodies employed in this
study are indicated (black horizontal lines). (B) PNKP protein levels in control patient-derived fibroblasts from an unaffected individual (1BR) and the
PNKP patient-derived fibroblasts MCSZ-I and AOA4/MCSZ, measured by western blotting using N- and C-terminal specific anti-PNKP antibodies.
Black asterisk denotes an unspecific band.  actin was employed as a loading control. (C) PNKP activity in control (1BR) and PNKP patient-derived
(MCSZ-I, AOA4/MCSZ) fibroblast cell extracts. TAMRA- or 6-FAM-labelled oligonucleotide duplex harbouring a SSBwith a 3′-phosphate or 5′-hydroxyl
terminus, respectively, was incubated with the indicated cell extracts (30 g total protein) for 10 min (to measure kinase and phosphatase activity) or 60 min
(to measure ligated product) at 37◦C prior to fractionation by denaturing PAGE. Arrows indicate the positions of the TAMRA- labelled 3′-phosphatase
substrate (‘18-nt 3′-P’), 6-FAM-labelled 5′-kinase substrate (‘21-nt 5′-OH’), and intermediates of their repair resulting from 3′-phosphatase activity (‘18-nt
3′-OH’), 5′-kinase activity (‘21-nt 5′-P’), DNA gap filling (‘19-mer’), and DNA ligation (‘40-nt’).
high-content imaging to quantify the level of H2AX, an
established and sensitive marker of DSBs (43,44), in PNKP
patient fibroblasts following treatment with ionizing radia-
tion (IR) or camptothecin (CPT); physiologically relevant
sources of DSBs that are substrates for PNKP. H2AX
levels rapidly increased in 1BR control fibroblasts within
30 min following IR, and declined to nearly background
levels over a subsequent 6 h repair period (Figure 2A and
Supplementary Figure S1A). Surprisingly, however, the
rate at which levels of IR-induced H2AX declined in
MCSZ and AOA4/MCSZ fibroblasts was similar to 1BR,
suggesting that the rate of DSBR in PNKP patient-derived
fibroblasts was largely normal. That these experiments
measured NHEJ was ensured by quantifying H2AX only
in cells in G1-phase of the cell cycle at the time of analysis,
which based on their cell cycle profile (Supplementary
Figure S1B) were primarily in G1 or G2 (>80%) at the time
of irradiation; cell cycle phases during which NHEJ is the
primary determinant of DSBR proficiency (45). Indeed,
treatment of wild type and PNKP patient fibroblasts with
an inhibitor of the NHEJ enzyme DNA-dependent protein
kinase (DNA-PKi) resulted, as expected, in a profound
defect in DSBR (Figure 2A and Supplementary Figure
S1A).
To examine whether NHEJ proficiency in the PNKP
patient-derived fibroblasts reflected the presence of resid-
ual PNKP activity we transfected the cells with PNKP
siRNA (Figure 2B). However, while we detected a small
increase in the persistence of H2AX in one of the two
PNKP patient-derived cell lines (AOA4/MCSZ) following
IR, this increase was not statistically significant (Figure
2C and Supplementary Figure S1C). The absence of a de-
tectable defect in DSBR was not restricted to DSBs in-
duced by IR, because we also failed to detect any signif-
icant difference in the accumulation of H2AX between
1BR control and AOA4/MCSZ patient fibroblasts follow-
ing treatment with camptothecin (CPT) (Figure 2D), which
promotes abortive TOP1 activity and induces DNA breaks
possessing 3′-phosphate and 5′-hydroxyl termini that are
substrates for both activities of PNKP (15,46). Collectively,
these results suggest that a defect in DSBR is not a cause of
the neuropathology that is associated with PNKP-mutated
diseases.
Reduced Rates of SSBR in PNKP Patient-Derived Fibrob-
lasts
Next, we examined the rate of SSBR in the PNKP patient-
derived fibroblasts by quantifying the level of nuclear
poly(ADP-ribose) in cells following DNA damage, in the
presence of an inhibitor of poly(ADP-ribose) glycohydro-
lase (PARG) to preserve the nascent polymer (7,47,48). This
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Figure 2. A normal rate of DSBR in PNKP patient-derived fibroblasts. (A) Representative scanR images (top) and quantification (bottom) of H2AX in
control (1BR) and PNKP patient-derived (MCSZ-I and AOA4/MCSZ) fibroblasts before and at the indicated times after ionizing radiation (2 Gy) in the
absence or presence of 5 M DNA-PK inhibitor (DNA-PKi was added 1 h before irradiation). Cell cycle populations were gated according to PCNA
positivity (S phase) and DNA content (G1 and G2) by DAPI staining. Only the data for G1 cells are shown. For quantification, data are normalized to
the 0.5 h time point and are the mean (±SEM) of three independent experiments. Statistical significance was determined by two-way ANOVA (ns, not
significant; ***P < 0.001). (B) DNA 3′-phosphatase activity and western blotting of cellular extracts from control 1BR and PNKP patient fibroblasts
(MCSZ-I and AOA4/MCSZ) transfected with non-target (NT) or PNKP siRNA. Oligonucleotide duplex substrate containing a SSB with a 3’-phosphate
terminus was incubated with cellular extracts for 10 min. (C) Quantification of H2AX in the indicated cell lines before and at the different times after
ionizing radiation (2 Gy). Cells were transfected with non-targeting siRNA (NT) or PNKP siRNA 48–72 h prior to irradiation. Quantification and statis-
tics were conducted as described in (A). Representative scanR images are shown in Supplementary Figure S1C. (D) Representative scanR images (left)
and quantification (right) of H2AX in the indicated cell lines after a 45 min incubation with DMSO vehicle or 10 M camptothecin (CPT). Data are
normalized to DMSO-treated control (1BR) cells and are the mean (±SEM) of three independent experiments. Statistical significance was determined by
one-tailed t-test (ns, not significant).
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sensitive immunofluorescence-based assay provides an indi-
rect measure of the level of chromosomal SSBs, analogous
to the measurement of H2AX as a marker of DSBs. In-
deed, incubation for short periods with PARG inhibitor un-
covered a significant increase in the level of nuclear ADP-
ribose in control 1BR fibroblasts following treatment with
2 Gy of IR, and as expected this level was much higher in
AOA-XRCC1 patient-derived fibroblasts in which SSBR is
known to be reduced (7) (Figure 3A). More importantly,
ADP-ribose was also greatly elevated in the AOA4/MCSZ
patient fibroblasts, indicative of a similar defect in SSBR
in these cells (Figure 3A). We also measured the level of
DSBs in these experiments in parallel, but did not detect
a difference between control and PNKP patient fibroblasts
(Supplementary Figure S2A). Notably, we also detected a
reduced rate of SSBR in both AOA4/MCSZ and MCSZ-
I patient fibroblasts in experiments in which we employed
a 10-fold higher dose of IR (20 Gy), to measure levels of
poly(ADP-ribose) in the absence of PARG inhibitor (Sup-
plementary Figure S2B).
To confirm the defect in SSBR in PNKP patient-derived
fibroblasts, we also quantified DNA strand breaks follow-
ing IR directly, using alkaline comet assays. Whilst this
assay detects both SSBs and DSBs, >95% of the DNA
strand breaks induced by IR are SSBs (49). Importantly,
in agreement with the nuclear ADP-ribose assay, the rate
at which SSBs declined following 20 Gy of IR was signif-
icantly slower both in XRCC1 and PNKP patient-derived
fibroblasts, when compared to the 1BR control (Figure 3B).
Finally, we also measured the induction and repair of SSBs
induced by the abortive activity of TOP1, following treat-
ment with CPT. Importantly, SSBs accumulated to a much
higher level in both of the PNKP patient-derived fibroblasts
during incubation with CPT, when compared to 1BR con-
trol cells, as measured by either nuclear ADP-ribose levels
or by alkaline comet assays (Figure 3C and D). We con-
clude from these experiments that whilst AOA4/MCSZ and
MCSZ-I cells exhibit normal rates of DSBR, they possess
reduced rates of SSBR.
Requirement for the DNA 5′-kinase, DNA 3′-phosphatase,
and FHA Domains of PNKP for SSBR
To examine which PNKP activities are responsible for
the SSBR defect in PNKP-mutated disease we conducted
complementation experiments, by transfecting purified
wild type and mutant recombinant PNKP proteins into
AOA4/MCSZ fibroblasts. AOA4/MCSZ fibroblasts were
employed because they possess the least amount of resid-
ual DNA3′-phosphatase activity and completely lack resid-
ual DNA 5′-kinase activity. As expected, recombinant
wild type histidine-tagged PNKP (His-PNKPWT) and His-
PNKPFHA harbouring a mutated FHA domain possessed
both DNA 5′-kinase activity and DNA 3′-phosphatase
activity, whereas His-PNKPPD harbouring a mutated 3′-
phosphatase domain lacked the latter (Figure 4A). We also
generated recombinant PNKP protein containing a point
mutation (K378A) that greatly reduces or ablates DNA ki-
nase activity, but this protein was relatively unstable when
transfected into cells and so was not utilized further (un-
published observations).
Whereas transfection with His-PNKPWT partially com-
plemented the SSBR defect in AOA4/MCSZ patient fi-
broblasts following IR, as measured by a decrease in the
level of nuclear ADP-ribose 30 min following irradiation,
transfection with His-PNKPPD failed to do so (Figure 4B).
This is consistent with the presence of 3′-phosphate at
∼70% of oxidative DNA breaks (14). We also examined
which PNKP activities were required to correct the de-
fect in repair of TOP1-induced SSBs, since this type of
SSB possess both 3′-phosphate and 5′-hydroxyl termini
(15). Surprisingly, both His-PNKPWT and His-PNKPPD
completely suppressed the elevated accumulation of TOP1-
induced SSBs in AOA4/MCSZ patient fibroblasts follow-
ing CPT treatment, as measured both by levels of nuclear
ADP-ribose and by alkaline comet assays (Figure 4C and
D). Similar results were obtained if we employed pEYFP-
tagged PNKP cDNA expression constructs, instead of re-
combinant protein (Supplementary Figure S3A). This re-
sult indicates that only theDNA5′-kinase activity of PNKP
is rate limiting for rapid repair of TOP1-induced SSBs
in AOA4/MCSZ fibroblasts. Notably, recombinant His-
PNKPFHA harbouring a mutated FHA domain failed to
restore full repair capacity in AOA4/MCSZ fibroblasts fol-
lowing either IR or CPT, confirming that the recruitment of
PNKP by XRCC1 is important for SSBR following either
oxidative stress or abortive TOP1 activity. Note that the in-
ability of transfected His-PNKPFHA to restore SSBR was
not due to differences in the level of transfected protein, be-
cause protein extracts prepared from cells transfected with
either His-PNKPWT or His-PNKPFHA possessed similar
levels of PNKP biochemical activity, as determined by their
ability to repair of an oligonucleotide substrate containing
both 5′-hydroxyl and 3′-phosphate termini (Supplementary
Figure S3B). Together, these data indicate a collective re-
quirement for all three domains of PNKP for efficient repair
of the range of SSBs that arise in cells.
SSBR functionality and the severity of PNKP-associated dis-
ease
Next, we examined whether the severity of PNKP-
associated disease is related to the level of residual PNKP
protein and/or activity during SSBR. To address this, we
first compared the level of PNKP protein in cells derived
from individuals with MCSZ with those from individu-
als with AOA4 or CMT2B2; the milder forms of PNKP-
mutated disease (Figure 5A). Whilst, PNKP protein lev-
els were greatly reduced in most of the patient-derived
LCLs and fibroblasts, there was no correlation between
the level of residual PNKP protein and pathological sever-
ity (Figure 5B). For example, the level of PNKP protein
in the CMT2B2 cell lines was generally no higher than in
the AOA4-I and MCSZ-I cell lines, despite the far milder
pathology associated with the former. Similarly, we did not
observe any strong correlation between disease severity and
the level of residual DNA 5′-kinase or DNA 3′-phosphatase
activity (Supplementary Figure S4A). For example, the level
of residual 3′-phosphatase activity in the CMT2B2 cell lines
was generally no higher than in cell lines from the more se-
vere diseases AOA4 and MCSZ, and the level of 5′-kinase
activity in MCSZ-I was higher than in cell lines from the
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Figure 3. A reduced rate of SSBR in PNKP patient-derived fibroblasts. (A) DNA single-strand breaks quantified by measuring nuclear ADP-ribose levels
in control (1BR) and PNKP patient-derived (AOA4/MCSZ) or XRCC1 patient-derived (AOA-XRCC1) fibroblasts before and at the indicated times
after treatment with ionizing radiation (2 Gy). Where indicated, cells were incubated in the presence of 10 M PARG inhibitor (PARGi) 30 min prior
to and after IR to suppress poly(ADP-ribose) degradation. Data were quantified by scanR high-content imaging and are the mean (±SEM) of three
independent experiments, with statistical significance determined by two-way ANOVA (***P< 0.001). Representative scanR images of single cell galleries
(from samples employing PARG inhibitor) are also shown (bottom). (B) DNA strand breaks quantified by alkaline comet assays in the indicated primary
fibroblasts before and at the indicated times after ionizing radiation (20 Gy). Data are the individual comet tail moments of 300 cells per sample combined
from three independent experiments. The horizontal bars show the mean tail moment of the 300 cells. Statistically significant differences were determined
using the individual means from the three independent experiments (100 cells/sample) by two-way ANOVA (***P < 0.001). (C) DNA strand breaks
quantified by measuring nuclear ADP-ribose levels in control (1BR) and PNKP patient-derived (MCSZ-I & AOA4/MCSZ) fibroblasts after incubation
for 45 min with DMSO vehicle or with 10 M camptothecin (CPT). Representative scanR images (left) and quantification (right) are shown. Data are
normalized to DMSO-treated 1BR cells and are the mean (±SEM) of seven independent experiments. Statistical analysis (one-tailed t-test) is indicated
(***P < 0.001; **P < 0.01). (D) DNA strand breaks quantified by alkaline comet assays in the indicated cell lines treated with DMSO vehicle or with 10
MCPT for 60 min. Data are as described in (B). Statistical significance was determined by one-tailed t-test (**P < 0.01; *P < 0.05).
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Figure 4. Importance of the PNKP DNA 5′-kinase, 3′-phosphatase, and FHA Domains for SSBR. (A) Cartoon (left) and enzymatic activity (right)
of the recombinant PNKP proteins employed here for complementation experiments. For activity assays, a 5′-TAMRA- and 3′-6-FAM- dual-labelled
oligonucleotide duplex (shown bottom) harbouring a SSB with both 3′-phosphate and 5′-hydroxyl termini was incubated for 10 min with the indicated
purified recombinant PNKPproteins prior to fractionation by denaturing PAGE.The positions of theTAMRA-labelled 3′-phosphatase substrate (‘18-nt 3′-
P’), 6-FAM-labelled 5′-kinase substrate (‘21-nt 5′-OH’), and the products of their processing by PNKP 3′-phosphatase activity (‘18-nt 3′-OH’) and 5′-kinase
activity (‘21-nt 5′-P’), respectively, are shown. (B) Representative scanR images (left) and quantification (right) of nuclear ADP-ribose in control fibroblasts
(1BR) and AOA4/MCSZ patient-derived fibroblasts 30 min following ionizing radiation (2 Gy) in the absence or presence of 10 M PARG inhibitor
(PARGi) as indicated. PARGi was added 30 min prior to irradiation. Cells were transfected with BSA or the indicated purified wild-type (PNKPWT) or
mutant (PNKPPD, PNKPFHA) PNKP proteins 18 h prior to irradiation. Data are normalized to DMSO-treated 1BR fibroblasts transfected with BSA
and are the mean (±SEM) of three independent experiments. Statistically significant differences were determined by one-tailed t-test (*P < 0.05; ns, not
significant). (C) Representative scanR images (top) and quantification (bottom) of nuclear ADP-ribose in the indicated cell lines after 45 min incubation
with DMSO vehicle or 10 M camptothecin (CPT). Cells were transfected in the presence of the indicated proteins 18 h prior to CPT treatment. Data are
as described in (B). (D) DNA strand breaks quantified by alkaline comet assays in the indicated cell lines following transfection with BSA or the indicated
recombinant PNKP proteins and treated 18 h later with DMSO vehicle or 10 M CPT for 60 min. Data are the individual comet tail moments of 300
cells per sample combined from three independent experiments. The horizontal bars show the mean tail moment. Statistically significant differences were
determined using the means from the three independent experiments (100 cells/sample by one-tailed t-test (*P < 0.05; **P < 0.01; ns, not significant).
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Figure 5. PNKP functionality and disease severity. (A) Cartoon depicting the location and type of PNKP mutations present in the MCSZ, AOA4 and
CMT2B2 patient-derived cell lines employed in this study. The details of the mutant alleles and the relevant citations are described in the materials and
methods. For homozygous mutations only one allele is depicted. (B) Western blot showing PNKP protein levels in the indicated control and PNKP patient-
derived fibroblasts (left) and LCLs (right).  actin was employed as a loading control. (C) Quantification of nuclear ADP-ribose in the indicated control
and PNKP patient-derived cells after 45 min incubation with DMSO vehicle or 10 M camptothecin (CPT). Data are normalized to DMSO-treated WT
cells and are the mean (±SEM) of four independent experiments. Statistically significant differences were determined by one-tailed t-test (**P < 0.01; *P
< 0.05). Representative scanR images are shown in Supplementary Figure S4B.
less severe diseases AOA4 and CMT2B2. Consequently, we
employed the sensitive nuclear ADP-ribose assay to exam-
ine whether disease severity correlated with the overall ef-
ficiency of SSBR in the different patient-derived cell lines.
Indeed, we detected elevated levels of ADP-ribose in all
of the patient-derived cell lines when compared to control
cells following treatment with CPT, and the level of CPT-
induced nuclear ADP-ribose in MCSZ and AOA4 cell lines
was higher than in cell lines from the far less severe disease,
CMT2B2 (Figure 5C and Supplementary Figure S4B). Col-
lectively, these data implicate reduced rates of SSBR as a
cause of PNKP-associated disease, and suggest that the ex-
tent of this reduction is a determinant of disease severity.
DISCUSSION
Reduced rates of SSBR, but not DSBR, in PNKP-mutated
disease
Mutations in PNKP result in several diseases spanning
a spectrum of neurological pathology, from neurodevel-
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opmental dysfunction in microcephaly with early-onset
seizures (MCSZ) through to moderate or mild/late-onset
neurodegeneration in AOA4 and CMT2B2, respectively. A
possible explanation why mutations in PNKP might cause
both neurodegeneration and neurodevelopmental dysfunc-
tion was the putative role for this protein in the repair
of both SSBs and DSBs. Surprisingly, however, we found
here that primary fibroblasts derived from individuals with
MCSZ or with combined AOA4/MCSZ exhibit normal
rates of DSBR following treatment with either ionising ra-
diation (IR) or camptothecin (CPT); physiologically rele-
vant sources of DSBs harbouring the 5′-hydroxyl and/or 3′-
phosphate termini that are substrates for PNKP (15). The
lack of a significant DSBR defect in PNKP-mutated cells
was surprising, because PNKP interacts with the critical
NHEJ protein XRCC4 (19,21,50) and has been reported
to be required for efficient NHEJ both in vitro and in cells
(19,20,42,51). It is unlikely that this result reflects a limi-
tation of our H2AX assay, because we readily detected
the expected defect in DSBR if the cells were incubated
with an inhibitor of the critical NHEJ protein, DNA-PKcs.
Whilst we cannot rule out that the pathogenic mutations in
PNKP result in measurable defects in DSBR specifically in
neurones this seems unlikely, because the defect in NHEJ
in similar microcephalic diseases resulting from mutations
in XRCC4, XLF/Cernnunos, or DNA ligase IV is read-
ily detected using patient-derived fibroblasts and assays of
the type employed here (38,40,52). One possible explana-
tion for our results is that the residual PNKP activity that
is present in the patient-derived fibroblasts is sufficient to
maintain DSBR proficiency. Perhaps consistent with this
idea, we noted that PNKP siRNA slightly increased the
level of residual H2AX in AOA4/MCSZ cells following
IR, albeit not statistically significantly. Alternatively, per-
haps other DNA 3′-end processing proteins can substitute
for PNKP during NHEJ (53). Irrespective of why DSBR
was largely normal in the PNKP patient-derived fibrob-
lasts employed here, our experiments suggest that a defect in
DSBR is unlikely to be the cause of PNKP-mutated disease.
In contrast to DSBR, the proficiency of SSBR in MCSZ
patient-derived fibroblasts was greatly reduced following ei-
ther IR or CPT. This is consistent with our previous analy-
ses, in which we detected similar defects in SSBR in lym-
phoblastoid cell lines derived from different MCSZ pa-
tients (54). The defect in SSBR detected here was appar-
ent whether we quantified SSBs directly by alkaline comet
assays or indirectly by measuring levels of nuclear ADP-
ribose. The additional use of the nuclear ADP-ribose assay
was important, because the greater sensitivity of this assay
allowed us to measure SSBs at the same low dose of IR
as that employed for measuring DSBs (2 Gy). In contrast
to cell lines derived from patients with MCSZ however, we
failed to detect any defect in SSBR following IR in the less
severe diseases AOA4 or CMT2B2 (unpublished observa-
tions). However, we did detect a defect in SSBR in AOA4
andCMT2B2 cell lines following treatment with CPT, using
this assay. Moreover, the defect in CMT2B2 cells following
CPT was less than that detected in either MCSZ or AOA4
cell lines, consistent with CMT2B2 being pathologically the
mildest of these diseases. Collectively, these experiments im-
plicate slower rates of SSBR as a cause of PNKP-mutated
disease, and suggest that the severity of this disease is related
to the level of SSBR capacity.
MCSZ and reduced DNA 3′-phosphatase functionality
It is currently unclear which of the two enzymatic activi-
ties of PNKP contribute most to the neuroprotective role
of this protein during SSBR. To address this, we compared
patient-derived cell lines from the different PNKP-mutated
diseases for levels of PNKP protein and its two biochemi-
cal activities. However, we failed to detect a correlation be-
tween disease severity and any of these parameters individ-
ually. It is possible that other factors contribute to disease
severity, such as an additive impact of the reduction in the
two PNKP catalytic activities or as yet unidentified differ-
ences in other DNA repair pathways. Alternatively, perhaps
the level of residual PNKP activity detected in vitro fails to
fully reflect the functionality of the mutant protein in cells.
Indeed, consistent with this idea, only cell lines from pa-
tients withMCSZ exhibited a reduced ability to repair chro-
mosomal SSBs induced by IR [this work and (54)]. Since
IR induces SSBs with 3′-phosphate termini this observa-
tion suggests that the DNA phosphatase functionality of
PNKP is lower in MCSZ cells than in AOA4 and CMT2B2
cells, despite the lack of a detectable difference in theirDNA
phosphatase activity in cell extracts in vitro. One possible
explanation for this discrepancy is that our biochemical as-
says are not sufficiently sensitive to detect pathologically
relevant differences between the DNA phosphatase activity
of the different patient cell lines. Alternatively, perhaps the
large truncation mutations that are common in MCSZ af-
fect not only the catalytic activity of PNKP but also its abil-
ity to be recruited and and/or stimulated by XRCC1. This
latter idea may explain why MCSZ-I cells, which retain rel-
atively high levels of residual PNKP activity but which har-
bour a mutated FHA domain, possess a defect in SSBR fol-
lowing IR. However, irrespective of why there is a discrep-
ancy between our biochemical and cellular assays, the ob-
servation that onlyMCSZ cell lines exhibit a defect in repair
of IR-induced SSBs implicates reduced PNKP-dependent
DNA phosphatase activity in the development of MCSZ.
In contrast to reduced DNA phosphatase activity, an
involvement of reduced DNA kinase activity in causing
MCSZ is less likely. For example, the AOA4 cell lines
(AOA4-I and AOA4-II) exhibited levels of SSBR following
CPT as low as those in MCSZ cells. Since we found here
that reduced SSBR following CPT is a measure of reduced
5′-DNA kinase function this suggests that reduced DNA
kinase activity does not, by itself at least, cause MCSZ.
This conclusion is also consistent with our previous obser-
vation that the PNKP point mutation E326K, which results
inMCSZ, reduces the proficiency of SSBR following IR but
not CPT (54).
Neurodegeneration and reduced DNA 5′-kinase functionality
In contrast to the neurodevelopmental pathology that
typifies MCSZ, it seems unlikely that reduced DNA 3′-
phosphatase functionality can account for the neurodegen-
erative pathology that typifies AOA4 and CMT2B2. For ex-
ample, as discussed above, whilst we readily detected a de-
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fect in the repair of IR-induced SSBs with 3′-phosphate ter-
mini in MCSZ cells, we failed to do so in cell lines from ei-
ther AOA4 or CMT2B2; the PNKP-mutated diseases that
are associated with neurodegeneration (data not shown).
Indeed, our data suggest that it is reduced DNA 5′-kinase
activity that is the major contributor and/or cause of the
neurodegeneration in PNKP-mutated disease, because we
detected reduced SSBR in all of our AOA4 and CMT2B2
cell lines following treatment with CPT, which as discussed
above is a measure of DNA 5′-kinase functionality. More-
over, the extent of this SSBR defect was greater in AOA4
than in CMT2B2 cells, consistent with the relative sever-
ity and/or age of onset of neurodegeneration in these dis-
eases. If reduced DNA 5′-kinase is a cause of neurodegener-
ation in PNKP-mutated disease then this pathology should
also be present in most patients with MCSZ, most of which
based on our analyses harbor residual DNA kinase activity
and rates of CPT-induced SSBR as low or lower thanAOA4
and CMT2B2. Indeed, while cerebellar atrophy and ataxia
was not initially reported as a feature ofMCSZ,more recent
case reports have reported this pathology (26–30).
Finally, our data have implications concerning the iden-
tity of the endogenous SSBs that trigger neurological dys-
function in PNKP-mutated disease. For example, if reduced
3′-phosphatase is indeed the cause of neurodevelopmen-
tal dysfunction these data implicate SSBs arising from ox-
idative stress in MCSZ, because this is a major source of
DNA breaks with 3′-phosphate termini. Similarly, if re-
duced DNA 5′-kinase activity is a cause of cerebellar ataxia
and neurodegeneration in PNKP-mutated disease our re-
sults implicate SSBs arising from abortive TOP1 activity
in AOA4 and CMT2B2, because this is a major source
of DNA breaks with 5′-hydroxyl termini. The latter ob-
servation is consistent with the molecular defect in the re-
lated SSBR-defective neurodegenerative disease, SCAN1,
which is similarly required for the repair of SSBs induced
by abortive TOP1 activity (8,55). It is also consistent with
recent reports that the repair of TOP1-induced SSBs is re-
duced in ataxia telangiectasia; the archetypal neurodegen-
erative disease associated with defects in DNA strand break
repair (56,57).
In summary, our data implicate reduced SSBR, but not
DSBR, as a cause of PNKP-mutated disease, and suggest
that the pathological severity of this disease is determined
by the nature and extent of this reduction. Moreover, our
data also highlight the two enzymatic activities of PNKP
in different aspects of the disease pathology, with reduced
DNA phosphatase and DNA kinase activity correlating
with neurodevelopmental dysfunction and neurodegenera-
tion, respectively.
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